1,5-diazocine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环化合物
• 英文名称: 1,5-diazocine
• 化学式: C₆H₆N₂
• 分子量: 106.13
• InChiKey: LLLMDRXIQZOTJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150259343A1

  公开（公告）日：2015-09-17

  The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor, and processes for preparing such compounds and compositions.

  本发明涉及携带环状取代基的三环六氢二氮杂喹啉类化合物，以及生产它们的方法，含有这类化合物的药物组合物，它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的药物，用于预防或治疗对5-HT2C受体调节产生反应的疾病和疾病的方法，以及制备这类化合物和组合物的方法。
• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US20170260158A1

  公开（公告）日：2017-09-14

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT 6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT 6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 6 receptor.

  本发明涉及公式I的喹啉化合物，其中变量的定义如索引和描述中所述。本发明还涉及含有这种化合物的药物组合物，以及它们作为5-HT6受体调节剂的用途，用于制备用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的药物，以及用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的方法。
• [EN] PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CARBONATES CYCLIQUES AVEC UN GROUPE VINYLIDÈNE EXOCYCLIQUE
  申请人：BASF SE

  公开号：WO2021144162A1

  公开（公告）日：2021-07-22

  The present invention relates to a process for preparing cyclic carbonates with an exocyclic vinylidene group by reacting a propargylic alcohol with CO2 in the presence of a silver catalyst having at least one bulky ligand and a lipophilic carboxylate ligand, where after completion of the reaction the catalyst is separated from the cyclic carbonate by the use two organic solvents of different polarity and having a miscibility gap, where the silver catalyst is enriched in the less polar solvent and the cyclic carbonate in the more polar solvent.

  本发明涉及一种制备具有外环乙烯基丙环碳酸酯的方法，该方法通过在至少具有一种笨重配体和一个亲脂性羧酸盐配体的银催化剂存在下，将丙炔醇与CO2反应，反应完成后，通过使用两种极性不同且具有混溶间隙的有机溶剂将催化剂与环状碳酸酯分离，其中银催化剂富集在较不极性的溶剂中，而环状碳酸酯富集在较极性的溶剂中。
• TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
  申请人：ABBVIE DEUTSCHLAND GMBH & CO. KG

  公开号：US20140080813A1

  公开（公告）日：2014-03-20

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.

  本发明涉及三环喹啉和喹啉衍生物，涉及含有这些化合物的药物组合物，以及它们作为5-HT2C受体调节剂，特别是激动剂或部分激动剂的用途，用于制备用于预防或治疗对5-HT2C受体调节有反应的病症和紊乱的药物，以及用于预防或治疗对5-HT2C受体调节有反应的病症和紊乱的方法。
• [EN] BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS FOR USE IN THERAPY<br/>[FR] COMPOSÉS AMIDE HÉTÉROAROMATIQUES BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS EN THÉRAPIE
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY

  公开号：WO2018229195A1

  公开（公告）日：2018-12-20

  The present invention relates to compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing such compounds; and to said compounds of the formula I or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; Y1 is N, NR5a, S, O or CR5b; Y2 is N, NR5c, S, O or CR5d; Z is N or C; with the proviso that at most two of X1, X2, X3 and X4 are N; with the proviso that Y1 is not O if Y2 is CR5d and simultaneously Z is C; with the proviso that Y1 and Y2 are not both simultaneously O or S; with the proviso that at least one of Y1, Y2 and Z is a heteroatom or heteroatom-containing group; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered optionally substituted, saturated, partially unsaturated or maximally unsaturated carbocyclic or heterocyclic ring; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6-alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5a, R5b, R5c, R5d, R6, R13, R14, R15 and R16 are as defined in the claims and the description.

  本发明涉及以下式I的化合物，或其互变异构体或药学上可接受的盐；涉及含有这些化合物的制药组合物；以及涉及将该式I的化合物，或其互变异构体或药学上可接受的盐用作药物，特别是用于治疗或预防以下疾病或疾病选组中的一种或多种：炎症性疾病，过度增殖性疾病或疾病，缺氧相关病理和以过度血管化为特征的疾病，其中X1为CR1或N; X2为CR2或N; X3为CR3或N; X4为CR4或N; Y1为N、NR5a、S、O或CR5b；Y2为N、NR5c、S、O或CR5d；Z为N或C；但前提是X1、X2、X3和X4中最多两个为N；但前提是如果Y2为CR5d且同时Z为C，则Y1不为O；但前提是Y1和Y2不同时为O或S；但前提是Y1、Y2和Z中至少有一个为杂原子或含杂原子的基团；L1为键，可选取代的C1-C6烷基或C3-C8环烷基；L2为键，可选取代的C1-C6烷基、C3-C8环烷基等；A为3、4、5、6、7或8成员的可选取代、饱和、部分不饱和或最大不饱和的碳环或杂环；或L2-A形成C1-C6烷基-OR13、C1-C6烷基-SR14或C1-C6烷基-NR15R16的基团；R1、R2、R3、R4、R5a、R5b、R5c、R5d、R6、R13、R14、R15和R16如权利要求和说明书中所定义。